[1] |
SWERDLOW S H, CAMPO E, HARRIS N L, et al. World Health Organization classification of tumours of haematopoietic and lymphoid tissues[M]. Lyon: IARC Press, 2017.
|
[2] |
ALAGGIO R, AMADOR C, ANAGNOSTOPOULOS I, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms[J]. Leukemia, 2022, 36(7): 1720-1748.
doi: 10.1038/s41375-022-01620-2
pmid: 35732829
|
[3] |
PETRICH A M, GANDHI M, JOVANOVIC B, et al. Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis[J]. Blood, 2014, 124(15): 2354-2361.
doi: 10.1182/blood-2014-05-578963
pmid: 25161267
|
[4] |
SARKOZY C, TRAVERSE-GLEHEN A, COIFFIER B. Double-hit and double-protein-expression lymphomas: aggressive and refractory lymphomas[J]. Lancet Oncol, 2015, 16(15): e555-e567.
doi: 10.1016/S1470-2045(15)00005-4
pmid: 26545844
|
[5] |
HOWLETT C, SNEDECOR S J, LANDSBURG D J, et al. Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis[J]. Br J Haematol, 2015, 170(4): 504-514.
doi: 10.1111/bjh.2015.170.issue-4
|
[6] |
OKI Y, NOORANI M, LIN P, et al. Double hit lymphoma: the MD Anderson Cancer Center clinical experience[J]. Br J Haematol, 2014, 166(6): 891-901.
doi: 10.1111/bjh.2014.166.issue-6
|
[7] |
ROSENTHAL A, YOUNES A. High grade B-cell lymphoma with rearrangements of MYC and BCL2 and/or BCL6: double hit and triple hit lymphomas and double expressing lymphoma[J]. Blood Rev, 2017, 31(2): 37-42.
|
[8] |
PEMMARAJU N, GILL J, GUPTA S, et al. Triple-hit lymphoma[J]. Proc (Bayl Univ Med Cent), 2014, 27(2): 125-127.
doi: 10.1080/08998280.2014.11929083
pmid: 24688198
|
[9] |
BACHER U, HAFERLACH T, ALPERMANN T, et al. Several lymphoma-specific genetic events in parallel can be found in mature B-cell neoplasms[J]. Genes Chromosomes Cancer, 2011, 50(1): 43-50.
doi: 10.1002/gcc.v50:1
|
[10] |
TOMITA N, TOKUNAKA M, NAKAMURA N, et al. Clinicopathological features of lymphoma/leukemia patients carrying both BCL2 and MYC translocations[J]. Haematologica, 2009, 94(7): 935-943.
doi: 10.3324/haematol.2008.005355
|
[11] |
MOTLLÓ C, GRAU J, JUNCÀ J, et al. Translocation (3;8)(q27;q24) in two cases of triple hit lymphoma[J]. Cancer Genet Cytogenet, 2010, 203(2): 328-332.
doi: 10.1016/j.cancergencyto.2010.08.018
|
[12] |
ELDESSOUKI T, HANLEY K, HAMADEH F, et al. “Triple hit” lymphomas: a retrospective cytology case series of an uncommon high grade B-cell malignancy with C-MYC, BCL-2 and BCL-6 rearrangements[J]. Diagn Cytopathol, 2018, 46(9): 807-811.
doi: 10.1002/dc.v46.9
|
[13] |
WANG W, HU S M, LU X Y, et al. Triple-hit B-cell lymphoma with MYC, BCL2, and BCL6 translocations/rearrangements: clinicopathologic features of 11 cases[J]. Am J Surg Pathol, 2015, 39(8): 1132-1139.
doi: 10.1097/PAS.0000000000000434
|
[14] |
HANS C P, WEISENBURGER D D, GREINER T C, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray[J]. Blood, 2004, 103(1): 275-282.
doi: 10.1182/blood-2003-05-1545
pmid: 14504078
|
[15] |
李敏, 张秋露, 赵炜, 等. 伴MYC、BCL2和(或)BCL6重排的高级别B细胞淋巴瘤在弥漫大B细胞淋巴瘤中的发生率[J]. 中华血液学杂志, 2021, 42(2): 124-128.
|
[16] |
LI M, ZHANG Q L, ZHAO W, et al. Incidence of high-grade B-cell lymphoma with MYC, BCL2, and/or BCL6 rearrangements in diffuse large B-cell lymphoma[J]. Chin J Hematol, 2021, 42(2): 124-128.
|
[17] |
HUANG W T, MEDEIROS L J, LIN P, et al. MYC/BCL2/BCL6 triple hit lymphoma: a study of 40 patients with a comparison to MYC/BCL2 and MYC/BCL6 double hit lymphomas[J]. Mod Pathol, 2018, 31(9): 1470-1478.
doi: 10.1038/s41379-018-0067-x
|
[18] |
ZHANG J J, WENG Z P, HUANG Y H, et al. High-grade B-cell lymphoma with MYC, BCL2, and/or BCL6 translocations/rearrangements: clinicopathologic features of 51 cases in a single institution of South China[J]. Am J Surg Pathol, 2020, 44(12): 1602-1611.
doi: 10.1097/PAS.0000000000001577
|
[19] |
TRAN J, VICKERS A, PONCE C P, et al. Triple-hit lymphoma of the cavernous sinus[J]. Can J Ophthalmol, 2019, 54(2): e61-e66.
doi: 10.1016/j.jcjo.2018.06.007
|
[20] |
EFSTATHOPOULOU A, GHIELMINI M, ZUCCA E. MYC/BCL2/BCL6 triple hit lymphoma of the pericardium: a case report and review of the literature[J]. J Cancer Res Clin Oncol, 2020, 146(9): 2435-2438.
doi: 10.1007/s00432-020-03137-6
pmid: 32025812
|
[21] |
ZHOU X, PAN H X, YANG P, et al. Both chronic HBV infection and naturally acquired HBV immunity confer increased risks of B-cell non-Hodgkin lymphoma[J]. BMC Cancer, 2019, 19(1): 477.
doi: 10.1186/s12885-019-5718-x
pmid: 31113483
|
[22] |
ABE S K, INOUE M, SAWADA N, et al. Hepatitis B and C virus infection and risk of lymphoid malignancies: a population-based cohort study (JPHC Study)[J]. Cancer Epidemiol, 2015, 39(4): 562-566.
doi: 10.1016/j.canep.2015.06.002
pmid: 26149122
|
[23] |
ENGELS E A, CHO E R, JEE S H. Hepatitis B virus infection and risk of non-Hodgkin lymphoma in South Korea: a cohort study[J]. Lancet Oncol, 2010, 11(9): 827-834.
doi: 10.1016/S1470-2045(10)70167-4
pmid: 20688564
|
[24] |
REN W, YE X, SU H, et al. Genetic landscape of hepatitis B virus-associated diffuse large B-cell lymphoma[J]. Blood, 2018; 131(24): 2670-2681.
doi: 10.1182/blood-2017-11-817601
pmid: 29545328
|
[25] |
DENG L J, SONG Y Q, YOUNG K H, et al. Hepatitis B virus-associated diffuse large B-cell lymphoma: unique clinical features, poor outcome, and hepatitis B surface antigen-driven origin[J]. Oncotarget, 2015, 6(28): 25061-25073.
doi: 10.18632/oncotarget.4677
pmid: 26314957
|
[26] |
AUKEMA S M, KREUZ M, KOHLER C W, et al. Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma[J]. Haematologica, 2014, 99(4): 726-735.
doi: 10.3324/haematol.2013.091827
|
[27] |
SWERDLOW S H. Diagnosis of ‘double hit’ diffuse large B-cell lymphoma and B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma: when and how, FISH versus IHC[J]. Hematology Am Soc Hematol Educ Program, 2014, 2014(1): 90-99.
|
[28] |
SCOTT D W, KING R L, STAIGER A M, et al. High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology[J]. Blood, 2018, 131(18): 2060-2064.
doi: 10.1182/blood-2017-12-820605
|
[29] |
PEDERSEN M Ø, GANG A O, POULSEN T S, et al. Double-hit BCL2/MYC translocations in a consecutive cohort of patients with large B-cell lymphoma-a single centre’s experience[J]. Eur J Haematol, 2012, 89(1): 63-71.
doi: 10.1111/ejh.2012.89.issue-1
|
[30] |
ZIEPERT M, LAZZI S, SANTI R, et al. A 70% cut-off for MYC protein expression in diffuse large B-cell lymphoma identifies a high-risk group of patients[J]. Haematologica, 2020, 105(11): 2667-2670.
doi: 10.3324/haematol.2019.235556
|
[31] |
CUCCUINI W, BRIERE J, MOUNIER N, et al. MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation[J]. Blood, 2012, 119(20): 4619-4624.
doi: 10.1182/blood-2012-01-406033
|
[32] |
KÜHNL A, CUNNINGHAM D, COUNSELL N, et al. Outcome of elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: results from the UK NCRI R-CHOP14V21 trial with combined analysis of molecular characteristics with the DSHNHL RICOVER-60 trial[J]. Ann Oncol, 2017, 28(7): 1540-1546.
doi: 10.1093/annonc/mdx128
pmid: 28398499
|
[33] |
GREEN T M, YOUNG K H, VISCO C, et al. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone[J]. J Clin Oncol, 2012, 30(28): 3460-3467.
pmid: 22665537
|
[34] |
GROSS T G, HALE G A, HE W S, et al. Hematopoietic stem cell transplantation for refractory or recurrent non-Hodgkin lymphoma in children and adolescents[J]. Biol Blood Marrow Transplant, 2010, 16(2): 223-230.
doi: 10.1016/j.bbmt.2009.09.021
|
[35] |
KANG J N, ZHANG Y Z, DING S, et al. Modified conditioning regimen with chidamide and high-dose rituximab for triple-hit lymphoma[J]. J Cell Mol Med, 2021, 25(22): 10770-10773.
doi: 10.1111/jcmm.16999
pmid: 34698437
|
[36] |
SNUDERL M, KOLMAN O K, CHEN Y B, et al. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma[J]. Am J Surg Pathol, 2010, 34(3): 327-340.
doi: 10.1097/PAS.0b013e3181cd3aeb
|
[37] |
VALERA A, LÓPEZ-GUILLERMO A, CARDESA-SALZMANN T, et al. MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy[J]. Haematologica, 2013, 98(10): 1554-1562.
doi: 10.3324/haematol.2013.086173
pmid: 23716551
|
[38] |
TZANKOV A, XU-MONETTE Z Y, GERHARD M, et al. Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP[J]. Mod Pathol, 2014, 27(7): 958-971.
doi: 10.1038/modpathol.2013.214
|
[39] |
ADAMS T, FUCHS D, SHADOAN P K, et al. Unexpected favorable outcome in a patient with high grade B-cell lymphoma with abnormalities of MYC, BCL6 and BCL2 loci[J]. Cancer Genet, 2018, 222-223: 25-31.
|